Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: The Occluded Artery Trial (OAT) biomarker ancillary study

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  Kruk, Mariusz ^a   Menon, Venu ^b   Kadziela, Jacek ^a   Sadowski, Zygmunt ^a   Ruzyłło, Witold ^a   Janas, Jadwiga ^a   Roik, Marek ^c   Opolski, Grzegorz ^c   Zmudka, Krzysztof ^d   Czunko, Piotr ^d   Kurowski, Michal ^e   Busz Papiez, Benita ^e   Zinka, Elzbieta ^f   Jablonski, Wojciech ^f   Jaworska, Krystyna ^g   Raczynska, Anna ^g   Skonieczny, Grzegorz ^g   Forman, Sandra ^h   Li, Daner ^h   Hochman, Judith ⁱ  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^e Department of General and Transplantation Surgery   (Poland)

^f Clinical Trials and Surveys Corporation ^*  (Poland)

^g Department of Endocrinology   (Poland)

^h Clinical Trials & Surveys Corp   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Biomarkers; Heart failure; Percutaneous coronary intervention; Remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; GALECTIN 3; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; FEMALE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART STRESS; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; VASCULAR PATENCY;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY OCCLUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84886069579     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-91     Document Type: Article

References (30)

1. Sadanandan S, Buller C, Menon V, Dzavik V, Terrin M, Thompson B, Lamas G, Hochman JS. The late open artery hypothesis-a decade later. Am Heart J 2001, 142:411-421. 10.1067/mhj.2001.117774, 11526353.
2. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006, 355:2395-2407. 10.1056/NEJMoa066139, 1995554, 17105759.
3. Udelson JE, Pearte CA, Kimmelstiel CD, et al. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J 2011, 161:611-621. 10.1016/j.ahj.2010.11.020, 3073850, 21392619.
4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998, 339:321-328. 10.1056/NEJM199807303390507, 9682046.
5. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003, 17:1105-1107.
6. Goetze JP, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004, 18:1928-1930.
7. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 97:1921-1929. 10.1161/01.CIR.97.19.1921, 9609085.
8. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004, 25:1788-1796. 10.1016/j.ehj.2004.07.038, 15474693.
9. Michtalik HJ, Yeh HC, Campbell CY, et al. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 2011, 107:1191-1195. 10.1016/j.amjcard.2010.12.018, 21296322.
10. Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003, 42:1909-1916. 10.1016/j.jacc.2003.07.015, 14662251.
11. Dzavík V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 2006, 114:2449-2457. 10.1161/CIRCULATIONAHA.106.669432, 2785021, 17105848.
12. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998, 32:1811-1818. 10.1016/S0735-1097(98)00464-1, 9857856.
13. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006, 69:604-613. 10.1016/j.cardiores.2005.10.002, 16360129.
14. Herzog E, Gu A, Kohmoto T, Burkhoff D, Hochman JS. Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non-infarct zones. Cardiovasc Pathol 1998, 7:307-312.
15. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309. 10.1161/01.CIR.103.18.2303, 11342481.
16. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530. 10.1161/01.RES.0000013290.12884.A3, 11909815.
17. Webb CS, Bonnema DD, Ahmed SH. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006, 114:1020-1027. 10.1161/CIRCULATIONAHA.105.600353, 16923753.
18. Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Cardiac Fail 2007, 13:843-849.
19. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28:711-718. 10.1093/eurheartj/ehm003, 2202923, 17339265.
20. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006, 48:15-20. 10.1016/j.jacc.2006.02.055, 16814643.
21. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004, 10:328-333. 10.1016/j.cardfail.2003.11.003, 15309700.
22. Matsunaga T, Abe N, Kameda K, et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 2005, 105:203-208. 10.1016/j.ijcard.2005.01.011, 16243114.
23. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992, 267:4583-4591.
24. Sato H, Takino T, Kinoshita T, et al. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett 1996, 385:238-240. 10.1016/0014-5793(96)00389-4, 8647259.
25. Kandalam V, Basu R, Abraham T, et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010, 106:796-808. 10.1161/CIRCRESAHA.109.209189, 20056917.
26. Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000, 35:968-973. 10.1016/S0735-1097(99)00632-4, 10732896.
27. Heeschen C, Dimmeler S, Hamm CW, et al. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003, 107:524-530. 10.1161/01.CIR.0000048183.37648.1A, 12566361.
28. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8. 10.1007/s11897-010-0004-x, 2831188, 20425490.
29. Sharma UC, Pokharel S, van Brakel TJ. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128. 10.1161/01.CIR.0000147181.65298.4D, 15520318.
30. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224. 10.1016/j.jacc.2006.03.061, 16979009.